Troubled Teva's successor to Copaxone just failed a big PhIII test for multiple sclerosis
After years of setbacks, delays and sundry frustrations, a deeply troubled Teva says that a late-stage trial for laquinimod — long billed as a successor to the aging flagship therapy Copaxone for multiple sclerosis — failed the test on the relapsing-remitting form of the disease.
Teva’s drug — heralded as its brightest pipeline prospect — did not meet the primary endpoint, trying to significantly improve the time to disability progression compared to placebo after three months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.